Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 32Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Ovarian Neoplasms 7Multiple Myeloma 6Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 4Hematologic Neoplasms 4Solid Tumors 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Solid Tumor 2Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Histologic Type 2Leukemia, Myelomonocytic, Chronic 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Carboplatin 339Cisplatin 238Paclitaxel 203Radiotherapy 194Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 140Erlotinib Hydrochloride 107Etoposide 98Magnetic Resonance Spectroscopy 92Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 71durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49Irinotecan 42atezolizumab 41Topotecan 39Radiation 39Biopsy 39Cyclophosphamide 38Standard of Care 37Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × cobimetinib × Clear all
NCT03202940 2026-05-08

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Massachusetts General Hospital

Phase 1/2 Active not recruiting
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
51 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡